Shots:
Immunology focuses on analyzing all aspects of the immune system in both healthy and diseased states, from its structure & function to its disorders, blood banking, immunization & organ transplant
Along with the enhanced utilization of immunotherapies for immunological & autoimmune diseases, monoclonal antibodies have also showcased a great potential to be used as…
The US FDA has approved 6 NDAs in Apr 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 26 novel products in 2022
In Apr 2022, the major highlights drugs were Vivjoa for Recurrent Vulvovaginal Candidiasis, Cuvrior for Stable Wilson’s Disease, Igalmi for Acute Treatment of Agitation…
The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022
In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…
While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios
While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…
Shots:
The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination.
SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…
Shots:
The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020.
Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B.
This article is based on the 2021…
The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M
The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…
Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy
Our team at PharmaShots has compiled a list of top 20 oncology companies based on…
Immunology deals with the physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders
With the new advancement in the immune sector- global pharmaceuticals continue to grow in the field despite the disruption during COVID-19. As in 2019- Abbvie again secured…
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012
The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

